Evotec (EVT) Stock Price, News & Analysis

Company Overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Key Stats

• Today's Range: €5.13 to €5.39
• 50-Day Range: €4.12 to €5.88
• 52-Week Range: €5.06 to €21.69
• Volume: 525,655 shs
• Average Volume: 1.36 million shs
• Market Capitalization: €961.12 million
• P/E Ratio: N/A
• Dividend Yield: 2.63%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Financial Services
• Current Symbol: ETR:EVT
• CIK: N/A
• Web: www.evotec.com
• Phone: +49-40-560810
• Fax: N/A
• Employees: 5,061
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): (€0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 60.36
• P/E Growth: 0.98
• Net Income: -€179.29 million
• Net Margins: -26.02%
• Pretax Margin: N/A
• Return on Equity: -24.55%
• Return on Assets: 0.97%

Debt

• Debt-to-Equity Ratio: 12.67
• Current Ratio: 1.68
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: €733.14 million
• Price / Sales: 1.31
• Cash Flow: €1.50 per share
• Price / Cash Flow: 3.45
• Book Value: €9.24 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 185,544,981
• Free Float: N/A
• Market Cap: €961.12 million
• Optionable: Not Optionable
• Beta: 1.24